's Information

Duk-Woo Park, MD

Country Korea (Republic of)
Specialty Interventional Cardiologist
  1. Renal Safety Issues in Dyslipidemia Treatment: Why is it Important?
  2. Escalation and De-Escalation Strategy for CHIP-PCI Patients: The TAILORED-CHIP Trial
  3. DAPT Duration in Complex PCI: Unsettled or Already Established Issues?
  4. PCI Is Enough. - When PCI Should Not Be Standard Treatment
  5. Optimizing Follow-up Strategies Post Complex PCI: Answers from the POST-PCI Trial
  6. Celebration of LM PCI: Joy in Growth, Journeying Towards 25 Years
  7. TAVI Procedure Plan and How to Achieve Successful Results
  8. Make It Simple : TAVR Antithrombotics
  9. Optimal Duration of Antiplatelet Therapy Following Left Main and Bifurcation PCI
  10. FATE-MAIN Trial
  11. TAILRORED-CHIP Trial
  12. Anticoagulation vs. Antiplatelet After TAVR: ADAPT-TAVR Trial
  13. Eagle's Eye View: How to Get Patients on a Statin Timely and Keep Them on It
  14. SAPIEN: Simpler and More Sophisticated (X4 and ALLIANCE)
  15. Insight from All Data of Left Main Revascularization (MAINCOMPARE, SYNTAX, PRECOMBAT, NOBLE, EXCEL)
  16. Edoxaban vs. DAPT for Valve Thrombosis and Cerebral Thromboembolism After TAVR: Deep-Dive into ADAPT-TAVR Trial
  17. Case 1. Left Main Disease
  18. DM and Triple Vessel Disease; Old Evidence and Next New Trials?
  19. My Approach to Left Main Coronary Disease - Master\'s Skill Secret
  20. LM Revascularization 2022: Guidelines and Concept Change
  21. Long-Term Valve Durability Issues and Optimal Decision-Making: TAVR or SAVR, Mechanical or Bioprosthetic?
  22. Key Message from the ADAPT-TAVR Trial: What We Learned?
  23. Leaflet Thrombosis, Is It Clinically Relevant?
  24. Racial Disparities in TAVR: Similarities and Differences
  25. Clinical Impact of Patient-Prosthesis Mismatch After TAVR
  26. Pragmatic Antithrombotic Strategies According to Bleeding and Ischemic Risk
  27. Two Road Diverged in a Cath Lab: PCI vs CABG in Complex PCI
  28. How to Optimize Sapien 3 Implantation for Future Management: FCA, Bicuspid, ViV, Low risk AS
  29. What Is Your Choice for Adherance Hypertensive Patients with Dyslipidemia?
  30. Escalation and De-Escalation Strategy for CHIP-PCI Patients: The Temporal Tuning in the TAILORED-CHIP Trial
  31. 10-Year Final Report of PRECOMBAT Trial: Deep-Dive
  32. My Challenging LM PCI Case of the Year
  33. East-Asian Paradox for Antithrombotics: Theory, Evidence and Next Strategy
  34. [Master\'s Keynote Lecture] Hand Down a Secret of Left Main PCI
  35. Antithrombotic and Antiplatelet Choice in Complex PCI
  36. Integrated Use of Imaging and Physiology in Left Main PCI
  37. Optimal Antithrombotics After TAVR
  38. Current Status of TAVR in Korea and US: TP-TAVR Registry
  39. TAVR Will Be a Standard Treatment for All Patients with Aortic Stenosis
  40. Balloon-Expandable SAPIEN 3 Valve
  41. Bifurcation PCI: Data, Evidence, and Guidelines
  42. Impact of Severe Coronary Artery Calcification on PCI Outcomes
  43. Optimal Antithrombotics After TAVR: Ongoing Trials
  44. OCT Versus IVUS for Guiding PCI: Current Evidences and Ongoing OCTIVUS Trial
  45. 10-Year Follow-Up of MAIN-COMPARE Registry and Substudies
  46. Anticoagulation for TAVR: GALILEO, and Yet It Moves.
  47. LM Bifurcation
  48. East-Asian Paradox: How to Optimize P2Y12 Inhibitors for Asians?
  49. How To Do Successful Registry Studies?
  50. Bifurcation PCI 2019: What Are Novel Changes for Technique or Concept?
  51. Highlighting 20 years of CV Protection with Lipitor
  52. PCI in Post-TAVR Patients: Beyond the Barrier
  53. Severe Coronary Calcification: Predictors, Managing Strategy, and Outcomes
  54. Integrated Use of FFR and IVUS in Non-LM Bifurcation PCI
  55. Clinical Impact of Periprocedural Myocardial Injury After TAVR
  56. Optimal Antithrombotic Therapy and Ongoing Clinical Trials
  57. Mainstream of TAVR: Minimalist Approach
  58. Permanent Pacemaker and Para-valvular Leakage: How to Avoid?
  59. Minimalist TAVR with Edwards SAPIEN 3 Valve
  60. Time to Consider Different P2Y12 Strategy for Complex PCI/CHIP Patients: From OPTIMA to TAILORED-PCI Trial
  61. Ture Distal Left Main PCI (Medina 1,1,1 or 1,0,1) Contemporary Strategy: Provisional vs. Complex
  62. Metallic DES Are All Equivalent!
  63. TAVR in Asia: Current Challenges and Future Direction
  64. Comparative Outcomes of Contemporary DES in Real-World: Is There Difference?
  65. EBC-MAIN Like Analysis Using the Largest Real-World Left Main Database
  66. Valve Thrombosis, Durability and Ongoing Antithrombotic Trials for TAVR
  67. OPTIMA Trial: P2Y12 Dose Adjustment for East-Asian ACS Patients
  68. Top 10 Tips on Bifurcation PCI
  69. Heavily Calcified Lesion: Rotational Atherectomy and Others
  70. Keynote Lecture on Bifurcation PCI: Expert\'s Concept and Technique
  71. TAVR - Moving to Lower Risk: STS or Age Per Se?
  72. Standard vs. Minimalist TAVR: When and How to Change?
  73. [Taped Case] TAVR with Sapien
  74. CTEPH; Diagnosis & Treatment
  75. All Contemporary DES Comparison; Data from Real-World Registry (IRIS-DES)
  76. Trends and Outcomes of Non-LM and LM Bifurcation PCI
  77. How Do I Choose Sapien 3, Evolut R or Lotus in My Practice?
  78. Long-Term Durability Issue of TAVR; Uncertainty or Would Be OK
  79. Contemporary Bifurcation PCI; How Advance over Time?
  80. Generalizability of EXCEL and NOBLE; Comparison with IRIS-MAIN Registry
  81. Where to Go? - Comparative Analysis: BMS, DES vs. BVS / - The Next Step: BVS in Challenging Lesions
  82. Can Different DES Make a Different Outcome?
  83. Future in Transcatheter Heart Valve Treatment
  84. SYNERGY : Latest Experience from Korea
  85. Growing Importance of Evidence in the Management of High CV Risk Patients
  86. How Much Promising BRS in Real-Practice PCI?; Updated Real-World Experience and Registry Data
  87. Bifurcation PCI Summary; Technique or Concept?
  88. BRS in Left Main PCI: Clinical Data and Experience
  89. DES Thrombosis and Restenosis: Still Problematic in Current Real-World with Updated DES
  90. Effect of Statin Therapy on Cardiovascular Outcome in Dyslipidemic Patients with CKD
  91. BVS: They Will Replace Metallic DES?
  92. Comparative Outcomes of New-Generation DES: IRIS-DES
  93. Can BVS Replace the Metal Stent?: Current Status and Future Perspective
  94. Shifting the Paradigm for Lipid Management: Pathways in Achieving Improved ASCVD Outcomes
  95. RDN; Indications & Evidence and Future
  96. Use of a Point-of-Care Platelet Function Assay to Improve the Prediction of Atherothrombotic Events after DES Implantation: ASAN-VerifyNow Registry
  97. Long-Term Outcomes After Stenting Versus Coronary Artery Bypass Grafting for Unprotected Left Main Coronary Artery Disease: 10-Year Results of Bare-Metal Stents and 5-Year Results of Drug-Eluting Stents From the ASAN–MAIN (ASAN Medical Center–Left MAIN Revascularization) Registry
  98. AMC Experience of the Intervention for the Structural Heart Disease
  99. Early DES - What Did We Learn - Updates from the ZEST Trial
  100. Alternative and Next Antiplatelet Therapy Beyond ADP Blocker
  101. Seeing Is Believing. IVUS Is A Mandatory in All Patients!
  102. DES vs. CABG for Multivessel Disease: Same or Different Interpretation from Registry to RCT
  103. Use of VH-Findings as Surrogate Marker for Anti-Atherosclerotic Drug
  104. Wrapping Up Current Clinical Trials and Future Study Program
  105. VH AMC Clinical Experience
  106. Meta-Analysis of 3,900 Patients with Left Main Disease Intervention (BMS vs DES vs CABG)
  107. Impact of DES on Diabetes Mellitus in Long Coronary Lesion
Conference Slides
Category